Dogwood Therapeutics Q3 2026 earnings

DWTX · 2026-11-05 08:45 BMO ET · 8-K on SEC · 10-Q on SEC

Net loss narrowed to $4.9 million as R&D expenses fell $11.2 million YoY due to the absence of a prior-year IPR&D charge, though cash declined $1.6 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$0.1M+$0.1M—Ex. 99.1, income statement
EPS (GAAP)-$0.14+$8.06—Ex. 99.1, income statement
EPS (adjusted)-$0.14+$8.06—Ex. 99.1, income statement
Net income-$4.88M+$10.86M—Ex. 99.1, income statement
Adj. EBITDA-$4.89M+$10.85M—Ex. 99.1, income statement
Adj. EBITDA margin-123.3%+69.1 pp—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 11.9% (prior 0.0%, change +11.9 pp)
  • Operating expenses $4.93M (+68.8% YoY)
  • One-offs in the quarter IPR&D impairment: $0 (vs $12.0M in Q3 2025); Loss on debt conversion: $0 (vs $6.13M in Q3 2025)
  • Effective tax rate 0.0% (prior-year 0.0%, year-to-date 10.4%)
  • Non-GAAP bridge No specific reconciliation provided; GAAP and adjusted figures are identical.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$4.95M$6.52M$6.52M-$1.57M
Weighted average shares outstanding34.13M34.13M1.92M+32.21M

Guidance

not stated in the 8-K

What drove it

  • Revenue story Licensing revenue of $0.1 million was recognized under the PRIDCor License Agreement.
  • EPS story The $8.06 improvement in EPS was driven by a $10.86 million reduction in net loss, primarily due to a $12.0 million decrease in R&D expenses.
  • One-off check IPR&D impairment: $0 (vs $12.0M in Q3 2025)

The good

  • R&D expenses decreased $11.2 million YoY as the prior-year IPR&D charge related to the Serpin Licensing Agreement was absent.
  • Net loss per share improved to -$0.14 from -$8.20.

The bad

  • Cash and cash equivalents declined $1.6 million to $4.95 million.
  • Total assets decreased $14.6 million to $75.6 million.
  • Total stockholders' equity decreased $10.8 million to $64.1 million.

The ugly

  • none

Open questions

  • The release states top-line results will be announced in November 2026 but does not provide the specific date.
  • The impact of the completed Halneuron Phase 2b trial on future R&D spending is not disclosed.
Full release

Dogwood Therapeutics (DWTX) earnings release, November 5, 2026

Dogwood Therapeutics, Inc. (DWTX) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Dogwood Therapeutics Announces Third Quarter 2026 Financial Results

-

Completed the Halneuron®

Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 -

- Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron® reduction in pain over three months of treatment with Halneuron®

-

-

Closed $5M Private Placement with Sealbond Limited, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc., to Advance Phase 3 Preparatory Activities -

ALPHARETTA, Ga., November 5, 2026 --

Dogwood Therapeutics, Inc.

(Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2026.

“Tens of millions of cancer patients worldwide previously treated with chemotherapy suffer from long-term, moderate-to-severe neuropathic pain (“CINP”),” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “Despite the massive unmet medical need associated with significant pain from ‘off-target’ chemotherapy-related nerve damage, there are no FDA approved medicines to treat CINP. Halneuron® has demonstrated statistically and/or clinically significant and durable pain reduction in cancer and CINP clinical trials to date. With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful,

Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”

Key Highlights¹

​

Third Quarter 2026 Financial Results

Revenue and CVR expense for the third quarter of 2026 were $0.1 million and $0.1 million, respectively, compared to no revenue and no CVR expense in the third quarter of 2025. In the third quarter of 2026, the Company received and recognized $0.1 million in licensing revenue for its first payment under the PRIDCor License Agreement and recognized cost of goods sold of $0.1 million related to the corresponding payment to its CVR Holders under the CVR Agreement.

Research and development expenses for the third quarter of 2026 were $3.3 million, compared to $14.5 million for the third quarter of 2025. The $11.2 million decrease year over year primarily related to a decrease in acquired in-process research and development (“IPR&D”) expenses of $12.0 million related to the Serpin Licensing Agreement that took place in the third quarter of 2025 offset by an increase in the Halneuron®

Phase 2b CINP study costs of $0.5 million, an increase in drug development and manufacturing costs of $0.2 million and an increase in salaries and related personnel costs of $0.1 million.

General and administrative expenses for the third quarter of 2026 were $1.6 million, compared to $1.3 million for the third quarter of 2025. The $0.3 million increase year over year was primarily due to increases in salaries and related personnel costs of $0.4 million offset by a decrease in legal and accounting fees of $0.1 million.

Net loss attributable to common stockholders for the third quarter of 2026 was $4.9 million, or $0.14 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $15.7 million, or $8.20 basic and diluted net loss per share, for the third quarter of 2025.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. Dogwood’s research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.

Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, Na

V

1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP.

SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Dogwood Therapeutics’ largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775).²

​

For more information, please visit www.dwtx.com.

Development and Commercialization Partnership Payments

To the extent that any payment to Dogwood resulting from the development and commercialization partnership constitutes either an “Upfront Payment” or a “Milestone Payment” under the terms and conditions applicable to the contingent value rights (“CVRs”) issued by Dogwood on October 17, 2024, Dogwood will cause any required amounts to be delivered to the rights agent for further payment to holders of the CVRs.

Financial statements

Income Statement

Condensed Consolidated Statements of Operations Data — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Licensing revenue100,000100,000$—
CVR expense88,10488,104
Gross profit11,89611,896
Operating expenses:
Research and development3,352,97714,521,3429,269,27519,528,283
General and administrative1,576,2191,287,7835,608,9154,633,883
IPR&D impairment9,190,897
Total operating expenses4,929,19615,809,12524,069,08724,162,166
Loss from operations-4,917,300-15,809,125-24,057,191-24,162,166
Other income (expense):
Sublease income27,24164,138
Loss on debt conversion with related party-6,134,120
Interest income, net42,03580,582185,73444,871
Exchange loss, net-35,757-17,509-72,186-36,251
Total other income (expense), net33,51963,073177,686-6,125,500
Loss before income taxes-4,883,781-15,746,052-23,879,505-30,287,666
Deferred income tax benefit (expense)8391,4362,480,340-189,255
Net Loss-4,882,942-15,744,616-21,399,165-30,476,921
Accrual of paid-in-kind dividends on Series A non-voting convertible preferred stock-1,256,662
Net loss attributable to common stockholders-4,882,942-15,744,616-21,399,165-31,733,583
Net loss per share of common stock — basic and diluted-0.14-8.2-0.63-18.02
Weighted average shares outstanding — basic and diluted34,129,5531,919,43333,936,7601,761,237

Balance Sheet

Condensed Consolidated Balance Sheet Data — (unaudited)

September 30, – 2026December 31, – 2025
Cash and cash equivalents4,948,2666,524,744
Total assets75,608,21990,171,237
Total liabilities11,475,00015,274,370
Total stockholders’ equity64,133,21974,896,867

Cash Flow

From the 10-Q · Nine Months Ended — (Unaudited)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Cash flows from operating activities
Net loss-21,399,165-30,476,921
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on foreign exchange72,18616,953
Amortization of loan costs52,373
Depreciation2,063
Reduction in carrying amount of right-of-use asset50,03049,553
Loss on debt conversion with related party6,134,120
Acquisition of license for research and development12,030,667
Deferred tax (benefit) expense-2,480,340189,255
IPR&D impairment9,190,897

Forward-Looking Statements:... (truncated)nties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission (the “SEC”). Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry

Managing Director

LifeSci Advisors, LLC daniel@lifesciadvisors.com

-Financial Tables Follow-³

​

DOGWOOD THERAPEUTICS

Selected Financial Data

(unaudited)

​

​⁴

​

​

Source: Dogwood Therapeutics, Inc.⁵

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.